“AI Policy Roadmap” Released by AdvaMed to Guide Regulators

On March 14, 2025, AdvaMed, the MedTech Association, launched its AI Policy Roadmap (the Roadmap) outlining coverage priorities for Congress and the U.S. Food and Drug Administration (FDA). The impetus for the Roadmap was the popularity of the necessary position that AI-enabled units will play in enhancing the accuracy and effectivity of illness analysis, enabling larger high quality therapies, and increasing entry to well being care and to progressive applied sciences. The Roadmap is damaged down into three primary coverage precedence areas: privateness and knowledge entry, FDA AI regulatory framework, and reimbursement and protection.

Privacy and Data Access

The Roadmap contends that one part of AI-enabled units that units them other than conventional know-how is the necessity for giant datasets to prepare and validate the algorithms underlying the units. The want for giant datasets creates two distinct challenges. 

• First, well being care knowledge is very fragmented and usually saved in non-standardized codecs. Health care knowledge is just not ceaselessly shared throughout well being programs, and there are only a few business distributors that present the providers obligatory to hyperlink and standardize this knowledge. 
• The second vital problem is the necessity to defend affected person privateness and make sure that knowledge safety is prioritized. To this finish, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires safety of sure kinds of private well being info, consent to use and/or disclose knowledge, and strict deidentification necessities when private well being info is used. The want for top of the range knowledge measured towards the necessity to defend affected person privateness creates an inherent rigidity in coverage priorities.

To mitigate this rigidity, the Roadmap gives three suggestions:

1. Congress and regulatory companies such because the FDA ought to guarantee knowledge safety with out stifling innovation.
2. Congress ought to consider the necessity to replace HIPAA for the AI period and create clear tips particularly for knowledge use in AI improvement.
3. Congress and regulatory companies ought to develop applicable tips round affected person discover and authorization for the information used to develop AI.

The Roadmap strives to steadiness the necessity for a excessive quantity of top of the range standardized knowledge with affected person privateness by inserting modernized consent and notification necessities on the middle of the coverage priorities. Recognizing the necessity for giant datasets, the Roadmap emphasizes modernizing conventional privateness insurance policies, comparable to HIPAA, to accommodate knowledge use and assortment for AI fashions. 

FDA AI Regulatory Framework

The FDA regulates sure AI-enabled units for security and efficacy. However, AI-enabled units require a unique method than FDA’s “conventional” medical machine assessment mannequin for these units that bear adjustments in an iterative style.  For accepted medical units that evolve  repeatedly, e.g., AI-enabled units, builders should submit for FDA assessment any modification that would considerably have an effect on the product’s security or effectiveness, in step with FDA-drafted steerage on the preapproval course of for post-market adjustments – referred to as predetermined change management plans (PCCP). These post-market adjustments happen as algorithms proceed to study and validate towards the information of the populations utilizing the know-how. The algorithms then alter primarily based on continued studying. While Congress handed laws authorizing PCCP approval in 2022, complete FDA PCCP steerage was solely launched in December of 2024. The full pre- and post-market processes for AI-enabled units are outlined within the FDA’s “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.”

The Roadmap’s suggestions recommend that FDA modernize laws to align with the rising shift from conventional medical units to AI-enabled units. Specifically, the Roadmap recommends that:

1. The FDA ought to stay the lead regulator answerable for overseeing the protection and effectiveness of AI-enabled medical units.
2. The FDA ought to implement the prevailing PCCP authority to guarantee it achieves its meant objective of making certain sufferers have well timed entry to optimistic product updates.
3. The FDA ought to problem well timed and present AI steerage paperwork associated to AI-enabled units and to prioritize the event and recognition of voluntary worldwide consensus requirements.
4. The FDA ought to set up a globally harmonized method to regulatory oversight of AI-enabled units.

The Roadmap commends progress made by Congress and the FDA to modernize legislative and regulatory processes relevant to AI-enabled units however urges continued deal with conserving tempo with technological innovation. The focus of the coverage suggestions is on streamlined, uniform laws that aren’t overly burdensome and won’t stifle innovation. 

Reimbursement and Coverage

Finally, the third coverage space addressed within the Roadmap is reimbursement and protection as a vital part of accelerating entry to digital well being applied sciences. Currently, reimbursement for AI-enabled units has been thought-about on a device-specific foundation, main to incremental coverage adjustments. The Roadmap means that Medicare, because the nation’s largest well being care payor supporting the medical wants of thousands and thousands of Americans, might be instrumental in shifting this coverage place. Further, Medicare coverage initiatives closely affect the protection insurance policies of personal payors and state Medicaid plans. While the Roadmap acknowledges that there isn’t a one single coverage resolution to enhance accessibility to digital well being know-how by way of reimbursement, “precisely capturing the fee and worth of [AI-enabled devices] is vital to making certain applicable reimbursement.”

Toward this finish, the Roadmap gives 5 coverage solutions:

1. Congress ought to think about legislative options to tackle the impression of funds neutrality constraints, or restraining Medicare spending to a sure outlined threshold, on the protection and adoption of AI applied sciences.
2. The Centers for Medicare & Medicaid Services (CMS) ought to develop a formalized fee pathway for algorithm-based well being care providers to guarantee future innovation and to defend entry to this subset of AI applied sciences for Medicare beneficiaries. 
3. To guarantee future innovation and to defend entry to algorithm-based well being care providers for Medicare beneficiaries, CMS ought to develop a formalized fee pathway for algorithm-based well being care providers.
4. Congress and the FDA ought to facilitate the adoption and reimbursement of digital therapeutics by way of laws and regulation.
5. CMS ought to leverage its authority to take a look at progressive different fee fashions to promote the flexibility of AI applied sciences to enhance affected person care and/or decrease prices.

The improvement and adoption of AI-enabled units to enhance analysis, remedy, and affected person care shall be amplified by the adoption of applicable reimbursement insurance policies as well being care suppliers and practitioners shall be extra readily in a position to find out about and use these well being care instruments. Sound reimbursement and protection insurance policies are an integral a part of supporting innovation and improvement of AI-enabled well being care units.

Conclusion

In a current press launch, Scott Whitaker, AdvaMed CEO and President stated in regards to the launch of the Roadmap, “The way forward for AI functions in medtech is huge and brilliant. It’s additionally largely to be decided. We’re in an period of discovery… This is the best time to promote the event of AI-enabled medtech to its fullest potential to serve all sufferers, no matter zip code or circumstance.” It is from this place of selling new know-how that AdvaMed urges Congress and the Food and Drug Administration to act in help of the event of AI-enabled medical know-how.

Foley is right here to show you how to tackle the brief and long-term impacts within the wake of regulatory adjustments. We have the sources to show you how to navigate these and different necessary authorized issues associated to enterprise operations and industry-specific points. Please attain out to the authors, your Foley relationship accomplice, or to our Health Care Practice Group and Health Care & Life Sciences Sector with any questions.

The publish “AI Policy Roadmap” Released by AdvaMed to Guide Regulators appeared first on Foley & Lardner LLP.